Bicuspid Aortic Valve and the End of a Promising Football Career
At 22, Keelan Williams has had to do what no young athlete expects to face: step away from elite football because of heart failure. The former Liverpool and Burnley academy player, once considered a Wales youth prospect, reached the point where exertion on the pitch left him breathless, heavy-legged and unable to perform at the level he knew was required. After two open-heart surgeries, two pacemaker implants and ongoing cardiology follow-up, the gap between recovery and full athletic capacity remained too wide to ignore.
His story is a stark reminder that congenital heart disease can sit quietly for years before becoming clinically decisive.
Williams was diagnosed with a bicuspid aortic valve at 15, a structural abnormality in which the aortic valve has two leaflets rather than the usual three. In many young people, the condition is found incidentally, long before symptoms appear. In his case, the first warning emerged during a Wales Under-16s camp, when a routine check-up found a murmur and triggered further assessment in Liverpool. That work-up identified the valve abnormality and a slight leak, but he had no symptoms at the time and was able to continue playing.
For several years, the diagnosis functioned more as a monitoring issue than a career-ending problem. That changed after another routine check-up in late 2024 showed the leak had worsened and surgery was now required. In January 2025, he underwent valve-sparing aortic root replacement surgery and then received a dual-chamber pacemaker. Postoperative complications followed: sepsis, a collapsed lung and respiratory failure led to an 11-day stay in intensive care.
When Recovery Does Not Restore Athletic Function
Even after the second operation in September 2025, the physiological picture did not improve enough for elite sport. When Williams returned to activity, he found he could not sprint, could not sustain match intensity and could not recover in the way a young professional footballer normally expects. He initially assumed the problem was deconditioning after surgery. The later data told a different story: his left ventricular function had fallen into the range consistent with stage-one heart failure, with an ejection fraction of 37%.
Most healthy adults have a left ventricular ejection fraction between 50% and 70%. A value of 37% means the heart is pumping less effectively than normal, and for a high-performance athlete the deficit becomes obvious quickly. The cardiovascular reserve needed for repeated acceleration, abrupt deceleration and sustained pressing simply is not there. In practical terms, that means the body reaches its limit sooner and recovers more slowly between efforts. For Williams, that translated into a lived reality of persistent fatigue and disproportionate breathlessness.
Medication was added to support his cardiac function, and he now takes five tablets daily. His pacemaker was also upgraded. Even then, the next echocardiogram showed only minimal improvement, with his ejection fraction rising to 38%. The change was too small to alter the central issue: his heart remained impaired, and competitive football was no longer medically realistic.
Why Routine Screening Changed His Outcome
Williams credits routine screening with finding the problem before symptoms forced the issue. During the Wales youth camp, a check-up identified the murmur before travel, leading to the diagnosis that altered the course of his career. Without that screening pathway, the bicuspid valve and leak might have remained hidden for longer. In congenital cardiac disease, early detection can shift management from emergency intervention to planned surveillance, and in some cases that is the difference between controlled risk and sudden deterioration.
His family has since undergone testing, with no similar heart condition found in other relatives. His case therefore appears isolated within the family, even though bicuspid aortic valve disease is congenital and can appear without warning. For clinicians, the story reinforces the value of screening in athletes who place repeated cardiovascular stress on the body, especially when a murmur or unexplained performance drop appears.
Williams now attends heart failure, cardiology and pacemaker clinics regularly. His medical life is built around surveillance, medication adjustment and device follow-up rather than training blocks and match preparation. The shift is abrupt, but it is also familiar to cardiologists: once ventricular function falls and symptoms persist despite intervention, the threshold for continued high-intensity sport becomes hard to justify.
A Message to Players Outside the Top Tier
Williams wants players across the sport to seek heart checks even when their clubs do not provide them routinely. Elite academies and top-flight environments often have access to screening, but that safety net is not universal across the football pyramid. His warning is direct because his own diagnosis came through a structured medical pathway rather than through symptom-driven crisis.
“I had no symptoms whatsoever,” he said, describing the original finding. “I was lucky in many senses that I played for Liverpool and Wales because if I didn’t, I may have never known that I had a leak in my valve.”
The clinical significance is hard to miss. Athletes can appear entirely well while a structural lesion is progressing underneath the surface. The first obvious sign may be reduced performance, shortness of breath or fatigue, but by then the disease may already have advanced far enough to require surgery or permanent changes in activity. In Williams’ case, the warning signs emerged only after the heart had already been through multiple procedures and still failed to recover enough for professional football.
He has framed retirement as disappointing but necessary. Family support, social media encouragement and his brother Neco Williams’ continued success have helped him adjust, yet the medical facts remain fixed. A congenital valve abnormality, worsening leakage, two operations, pacemaker therapy and persistent low ejection fraction left no safe route back to the game.
The case leaves one immediate clinical question open: how many young athletes with silent valve disease or other inherited cardiac abnormalities are still moving through sport without screening?